Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Aspirin resistance relevant GPIa gene polymorphic site and application

A technology of aspirin and genes, applied in the field of drug selection for medical disease treatment, can solve problems such as uncertain gene polymorphisms, and achieve the effect of reducing the recurrence rate of stroke

Inactive Publication Date: 2015-09-23
武汉欧瑞康安生物科技有限公司
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to incomplete statistics, clinical aspirin resistance is as high as 40% of patients, but because there are many targets that affect the action of aspirin, so far, the gene polymorphisms related to aspirin resistance are still uncertain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aspirin resistance relevant GPIa gene polymorphic site and application
  • Aspirin resistance relevant GPIa gene polymorphic site and application
  • Aspirin resistance relevant GPIa gene polymorphic site and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Discovery of GP Ⅰ a gene polymorphism (C807T) associated with aspirin resistance:

[0028] The data of stroke patients from 2010 to 2014 were retrieved from the stroke database, and according to the diagnostic criteria of ischemic stroke, patients diagnosed with ischemic stroke were screened, and aspirin was further selected for secondary prevention (secondary prevention is for patients with cerebral palsy). For patients with stroke symptoms or after stroke, these people need to prevent reoccurrence of stroke) as the total sample (5033 people in total).

[0029] 1. Determine the number of people with stroke recurrence in the total sample, and explore the relationship between the polymorphism of the GP Ⅰ a (C807T) gene and stroke recurrence in the total sample (Table 2);

[0030] 2. In the total sample, patients who returned to the hospital for follow-up visits (including those who have relapsed and those who have not relapsed, a total of 3429 people), collected peripher...

Embodiment 2

[0046] Application of primers for GP Ⅰ a gene polymorphism site (C807T) related to aspirin resistance in the preparation of kits for screening aspirin resistance patients:

[0047]All patients with ischemic stroke for the first time were given aspirin for secondary prevention, and the patients were followed up 3 months later to detect the ARU and stroke recurrence of each patient. At the same time, the peripheral blood of the patients was collected to detect the presence of GP Ⅰ a (C807T) polymorphism by gene sequencing, and the incidence of aspirin resistance in mutant and wild-type patients was analyzed.

[0048] The study began in August 2013, and the deadline for case inclusion was August 2014. According to the diagnostic criteria for ischemic stroke,

[0049] Patients diagnosed with ischemic stroke were selected as the research objects, and the following tasks were completed:

[0050] 1. According to the guidelines for the secondary prevention of ischemic stroke, aspirin...

Embodiment 3

[0060] Discovery of the COX-1 gene polymorphism (A842G) associated with aspirin resistance:

[0061] With the same stroke database, blood sample and method as in Example 1, the relationship between the polymorphism of the COX-1 (A842G) gene and stroke recurrence in the total sample (5033 people in total, the same as in Example 1) was detected (Table 6); And the relationship between the polymorphism of COX-1 (A842G) gene and ARU ≥ 550 in patients returning to the hospital for follow-up visits (including relapsed and non-relapsed patients, a total of 3429 people, the same as in Example 1) (Table 5).

[0062] The results showed that among ischemic stroke patients taking aspirin for secondary prevention, compared with wild-type patients, the COX-1(A842G) mutant group had a significantly higher aspirin response unit ARU value, and the number of patients with ARU≥550 was significantly higher than the wild-type group (Table 5); at the same time, the recurrence rate of stroke was also...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an aspirin resistance relevant GPIa gene polymorphic site and application. Antiplatelet drugs (especially aspirin) have great significance in treatment of ischemic stroke, but the current survey result shows that many patients in ischemic stroke relapse into the stroke even after taking the antiplatelet drugs, and the phenomenon is called as antiplatelet drug resistance. The applicant determines the aspirin resistance relevant GPIa gene polymorphic site GPIa(C807T), and designs a primer for detecting the polymorphism of the site for the site, the primer can be used for preparing a kit for screening out aspirin resistance patients so as to select antiplatelet drugs for patients of ischemic stroke, and the aspirin resistance and stroke relapse rate are decreased.

Description

technical field [0001] The invention relates to the field of drug selection for medical disease treatment, in particular to the polymorphic site of GP I a gene related to aspirin resistance and its application. technical background [0002] With the aging population in our country, the incidence of cerebrovascular disease is increasing year by year. The latest survey results show that cerebrovascular disease has become the number one killer of Chinese people beyond tumors since 2010. There are 2 million new cases in my country every year. Chronic cerebrovascular disease accounts for 70-80%, recurrent patients account for 27%, and 70% of patients have neurological deficits. The high mortality rate, disability rate and recurrence rate of cerebrovascular disease have caused a great social burden and economic burden. burden. Antiplatelet drugs (especially aspirin) play a vital role in the prevention and treatment of cerebrovascular diseases, but the current survey results show th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6883C12Q1/6876C12Q2600/106C12Q2600/136C12Q2600/156
Inventor 胡波毛玲夏远鹏贺权威靳慧娟李亚男
Owner 武汉欧瑞康安生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com